Results 41 to 50 of about 23,927 (264)

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

American Journal of Hematology, EarlyView.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong, Tamara Wais, Cecilia Varga, Christina Schueller, Sarada Achyutuni, Robert Kralovics   +5 more
wiley   +1 more source

Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective studyResearch in context

EClinicalMedicine
Summary: Background: Essential thrombocythemia (ET), a myeloproliferative neoplasm (MPN), has a substantial risk of evolving into post-essential thrombocythemia myelofibrosis (post-ET MF).
Danhong Xiang, Xiudi Yang, Honglan Qian, Li Zhang, Yanxia Han, Yongcheng Sun, Ying Lu, Yu Chen, Dan Cao, Meiwei Hu, Lifeng Wang, Qinli Tang, Dijiong Wu, Guoyan Tian, Hongyan Tong, Jie Jin, Jian Huang   +16 more
doaj   +1 more source

Neurological disorders in essential thrombocythemia

Haematologica, 2011
Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy.
Segolene Billot, Eirini G. Kouroupi, Johan Le Guilloux, Bruno Cassinat, Caroline Jardin, Thierry Laperche, Pierre Fenaux, Antoine F. Carpentier, Jean-Jacques Kiladjian   +8 more
doaj   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Imaging Flow Cytometry Detection of Cytogenetic Abnormalities in Circulating CD34+ Cells Predicts Leukemic Transformation in Myelofibrosis

Cytometry Part A, EarlyView.
ABSTRACT Myelofibrosis is a myeloproliferative neoplasm with potential to transform to acute myeloid leukemia. This evolution is unpredictable and current assays lack the sensitivity and applicability needed to predict this transformation. While population‐level data utilizing comprehensive genomic profiling can identify subgroups at higher risk of ...
Ruby M. Hamilton, Ryan J. Collinson, Henry Y. Hui, Zi Yun Ng, Hun S. Chuah, Malcolm Webb, Belinda B. Guo, Wendy N. Erber, Kathy A. Fuller   +8 more
wiley   +1 more source

Modern Approaches to Diagnosis and Treatment of Essential Thrombocythemia: Literature Review and Own Experience

Клиническая онкогематология, 2015
Objective. The aim of our study was to present literature data and own experience about epidemiology, terminology, etiology and pathogenesis of еssential thrombocythemia. Methods.
K. M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival

European Journal of Haematology, EarlyView.
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander   +5 more
wiley   +1 more source

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja, Savić Aleksandar, Ilić Tatjana, Milošević Ivana, Maksimović Marina, Vučković Biljana   +5 more
doaj   +1 more source

Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]

, 2010
Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +1 more source

Biomolecular and histological features in pediatric essential thrombocythemia: adequacy of who diagnostic criteria [PDF]

, 2017
Myeloproliferative neoplasms (MPN), Essential Thrombocythemia (ET), Polycythemia Vera (PV) and primary myelofibrosis (PMF), are clonal disorders of the hematopoietic stem cell.
Bertozzi, Irene
core   +1 more source